Hadi Valizadeh

Hadi Valizadeh


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in Journal of Controlled Release
Verified
Journal Article
Closed access
FZFahimeh Zahednezhad
Fahimeh Zahednezhad
MSMaryam Saadat
Maryam Saadat
HVHadi Valizadeh
Hadi Valizadeh
PZParvin Zakeri-Milani
Parvin Zakeri-Milani
Behzad BaradaranBehzad Baradaran
Behzad Baradaran

1 June 2015 in Advanced Pharmaceutical Bulletin
Verified
Journal Article
Open access
JDJafar Ezzati Nazhad Dolatabadi
Jafar Ezzati Nazhad Dolatabadi
HVHadi Valizadeh
Hadi Valizadeh
HHHamed Hamishehkar
Hamed Hamishehkar
Solid Lipid Nanoparticles as Efficient Drug and Gene Delivery Systems: Recent Breakthroughs

1 June 2021 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
SMSolmaz Mojarad-Jabali
Solmaz Mojarad-Jabali
MFMasoud Farshbaf
Masoud Farshbaf
PWPaul R Walker
Paul R Walker
SHSalar Hemmati
Salar Hemmati
Yousef FatahiYousef Fatahi
Yousef Fatahi
HVHadi Valizadeh
Hadi Valizadeh

1 October 2016 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
SNSaeedeh Najafi-Hajivar
Saeedeh Najafi-Hajivar
PZParvin Zakeri-Milani
Parvin Zakeri-Milani
HMHamed Mohammadi
Hamed Mohammadi
MNMehri Niazi
Mehri Niazi
MSMehdi Soleymani-Goloujeh
Mehdi Soleymani-Goloujeh
HVHadi Valizadeh
Hadi Valizadeh

1 December 2020 in Journal of Controlled Release
Verified
Journal Article
Open access
MFMasoud Farshbaf
Masoud Farshbaf
AKAhmad Yari Khosroushahi
Ahmad Yari Khosroushahi
SMSolmaz Mojarad-Jabali
Solmaz Mojarad-Jabali
AZAmir Zarebkohan
Amir Zarebkohan
HVHadi Valizadeh
Hadi Valizadeh
PWPaul R Walker
Paul R Walker
As one of the deadliest diseases, cancer frequently resists existing therapeutics because they do not target all cells within a progressing tumor, for example both tumor stem and proliferating cells. This frequently results in enrichment of invasive and metastatic drug-resistant tumor cells subpopulations, cancer recurrence and eventually, patient mortality. Thus, there is an urgent need to identify specific markers, by which the targeted imaging and/or therapeutic "guided missile"-like agents can specifically detect and/or eradicate all cancer cells within a heterogeneous tumor, while leaving the normal cells intact. As a member of heat shock protein 70 (HSP70) superfamily, glucose regulated protein 78 (GRP78) has been documented as a molecular chaperone in the endoplasmic reticulum (ER) which mainly responds to ER stresses in normal cells. There is over-expression of GRP78 on the surface of cancer cells and angiogenic endothelial cells, which makes it a promising target for different types of peptides and antibodies that can be employed for targeted cancer therapy or imaging. In this review, we discuss the biological processes, functional importance and translocation mechanisms of cell surface GRP78 (csGRP78) in tumor cells. As a cancer biomarker, we also review the potential applications of csGRP78 targeted therapy and imaging and finally we suggest a brief roadmap ahead of csGRP78 targeting for targeted theranostic implications.

1 May 2014 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
JDJafar Ezzati Nazhad Dolatabadi
Jafar Ezzati Nazhad Dolatabadi
HHHamed Hamishehkar
Hamed Hamishehkar
MEMorteza Eskandani
Morteza Eskandani
HVHadi Valizadeh
Hadi Valizadeh